Friday, 20 Oct 2017

You are here

Rheumatic IRAEs Gaining Speed

Today I was fortunate to be a part of a From Bench to Bedside session on the topic of controlling the balance between cancer and autoimmunity, chaired by Drs. Leonard Calabrese and Xavier Mariette. Rheumatic IRAEs from checkpoint inhibitor therapy are growing rapidly in scope and rheumatologists must be aware of these complications, as they are certain to encounter this type of patient.

The first talk was by Dr. Antony Rosen (JHU) who discussed possible mechanisms underlying cancer in the setting of autoimmune disease, focusing on the strong associated between RNA pol III positive systemic sclerosis and the development of cancer. Next up was Dr. Aurélien Marabelle (France) who spoke from the oncology perspective on the paradigm shift in cancer therapy from drugs that target cancers to these checkpoint inhibitors that target the patient’s own immune system. He stressed the importance of interprofessional care of these patients by oncology and rheumatology.

I was thrilled to present the first abstract on our Cleveland Clinic experience with rheumatic IRAEs thus far. In our experience it seems that rheumatic IRAEs may not be self-limiting like some of the other system IRAEs (skin, gut), but rather here to stay, making the role of the rheumatologist all the more important. Dr. Rakiba Belkhir (Paris) presented the final abstract and shared a case series of 6 patients who developed ACPA-positive RA on checkpoint therapy.

Tak away points stressed that rheumatologists must become familiar with rheumatic IRAEs and engage with oncologists inter-professionally to optimize patient care, as their frequency will continue to increase.

Add new comment

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.